„We must learn to create magical spheres that ... only hit the pathogens.”
Paul Ehrlich 1854-1915
SEPSIS UPDATE 2023: SMARTDYELIVERY BRINGS ITSELF UP TO DATE ON THE LATEST SEPSIS RESEARCH
From 6-8 September 2023 SmartDyeLivery took part in the 11th international congress on sepsis research in Weimar. With the motto „Immunotherapies – Advances and Adaptions“ the German Sepsis Society discussed the current situation of the critical care community. The meeting gave outstanding researchers the opportunity to report on the latest advances in immunomodulatory approaches to the adaptive immune response in sepsis.
SmartDyeLivery presented its innovative technology at the joint exhibitor booth with the team of InfectoGnostics Forschungscampus Jena e.V.
SMARTDYELIVERY CONVINCES EXISTING INVESTORS TO INCREASE THEIR PARTICIPATION
In the latest round of financing, both the Foundation for Technology, Innovation and Research Thuringia (STIFT) and an existing private investor increased their holdings. The investors were motivated by the company's latest milestone - the approval of the BfArM to conduct a first clinical trial on healthy subjects. STIFT aims to promote regional science and has been supporting the innovative therapeutic concept of SmartDyeLivery since 2018.
SMARTDYELIVERY RECEIVES APPROVAL FOR PHASE I CLINICAL TESTING
We’ve got reason to celebrate: After the examination of our clinical trial application, the Federal Institute for Drugs and Medical Devices (BfArM) has given permission to transition our first product into the clinical phase. Thus, nanocarriers that are developed for the treatment of septic liver failure can be tested on healthy subjects for the very first time.
DEVELOPMENT OF NEW THERAPY OPTIONS
In a first field of application we focus on the targeted transport of active substances in liver cells. We are thus creating a therapeutic option for the treatment of patients with septic cholestasis with the aim of reducing the extremely high mortality rate caused by this complication.